Publications by authors named "Yana Fedorova"
Article Synopsis
- Alzheimer's disease (AD) is a major neurodegenerative disorder affecting over 30 million elderly people worldwide, with projections suggesting this number could rise to 115 million by 2050.
- Current diagnostic methods include clinical assays for amyloid markers in cerebrospinal fluid (CSF), brain MRI, and PET scans, but predicting AD at asymptomatic stages remains a challenge.
- There is a growing interest in developing less invasive methods for early detection, focusing on specific proteomic changes in blood plasma, which could pave the way for identifying risk factors and pathways involved in AD progression.
Early recognition of the risk of Alzheimer's disease (AD) onset is a global challenge that requires the development of reliable and affordable screening methods for wide-scale application. Proteomic studies of blood plasma are of particular relevance; however, the currently proposed differentiating markers are poorly consistent. The targeted quantitative multiple reaction monitoring (MRM) assay of the reported candidate biomarkers (CBs) can contribute to the creation of a consistent marker panel.
View Article and Find Full Text PDFType II restriction-modification (R-M) systems encode a restriction endonuclease that cleaves DNA at specific sites, and a methyltransferase that modifies same sites protecting them from restriction endonuclease cleavage. Type II R-M systems benefit bacteria by protecting them from bacteriophages. Many type II R-M systems are plasmid-based and thus capable of horizontal transfer.
View Article and Find Full Text PDF